Beruflich Dokumente
Kultur Dokumente
Pregabalin, (S)-3-(aminomethyl)-5-methylhexanoic
acid, also known as -isobutyl--aminobutyric acid,
or isobutyl-GABA, is a potent anticonvulsant1,
currently sold under trade name of Lyrica. The
drug, pregabalin has also been found to be useful for
treatment of various other conditions, like pain,
fibromyalgia, physiological conditions associated
with psychomotor stimulants, inflammation, gastrointestinal damage, insomnia, alcoholism and various
psychiatric disorders, including mania and bipolar
disorder2.
Syntheses of pregabalin via asymmetric as well as
achiral pathways are well reported. Generally,
synthesis of (S)-3-(aminomethyl)-5-methylhexanoic
acid is broadly categorized into three major
approaches: (i) resolution of (RS)-3-(aminomethyl)-5methylhexanoic acid via diastereomeric salt
formation3 (ii) synthesis via (S)-ethyl 3-cyano-5methylhexanoate3-7 and (iii) chiral or non-chiral
desymmetrization of 3-isobutyl glutaric anhydride8-10.
Some of the other methods for synthesis of (S)-3(aminomethyl)-5-methylhexanoic
acid
include
reductive amination of mucohalic acid and its
derivatives11, stereo-selective synthesis using chiral
auxiliaries such as (+)-4-methyl-5-phenyl-2-oxazolidinone12 and also through 2,2-dichloro-3-isobutylcyclobutanone13. Most of the above reported methods
1471
Scheme I
1472
Scheme II Reagents and conditions: (i) NH3, MeOH, 25C, 1.5 h; (ii) NH2CH(R)Ph, MeOH, 25C, 1 h; (iii) a) H2 (5 atm), 10 mol %
Pd/C (50 % wet and 10 % Pd loading), MeOH, RT, 8 h; (iv) H2 (25 atm), 10 mol % Pd/C (50 % wet and 10 % Pd loading), MeOH, RT,
8 h; (v) resolution as per reported method3
1473
Scheme III Reagents and conditions: (i) ROH, pTSA, toluene, reflux; 5 h; (ii) iso-butyraldehyde, potassium tert-butoxide, tertbutanol, RT, 24 h; (iii) H2 (5 atm), 5 mol % Pd/C (50% wet and 10% Pd loading, ethanol, RT, 5 h
Scheme IV Reagents and conditions: (i) Ethanol, pTSA, reflux; 12 h; (ii) H2 (10 atm), 5 mol % Pd/C (50% wet and 10% Pd loading),
Methanol, RT, 10 h; (iii) a) Thionyl chloride, 60C, 10 h; b) DCM, NH3, 1 h; (iv) Thionyl chloride, reflux; 12 h
Scheme V Reagents and conditions: (i) Aq. KOH, RT, 10 h; (ii) LiBH4, THF, reflux; 4 h
1474
Scheme VI Reagents and conditions: (i) NaNO2, H2SO4, KBr, water, 14C, 4 h (ii) a) SOCl2, 60C, 10 h; b) DCM, NH3,1 h; (iii)
P2O5, 80C, 12 mm Hg; iv) diethyl malonate, NaH, DMF, RT, 24 h; (v) H2O (1 equiv.), KCl, DMSO, 150C, 6 h.
Scheme VII Reagents and conditions: (i) iso-butyraldehyde, piperidine/acetic acid, H2 (5 atm) 2 mol % Pd/C (50% wet and 10% Pd
loading), methanol, RT, 5 h; (ii) Cs2CO3, ethyl chloro acetate, 65C, 2 h; or K2CO3, ethyl chloro acetate, 90C, 3 h (iii) CsCl, DMSO,
170C, 4 h; (iv) Cs2CO3, thiophenol, DMF, 130C, 4 h.
(S)-2-Bromo-4-methyl-pentanenitrile
18
was
prepared from L-leucine 15 as per reported method20,
which on SN2 displacement with diethyl malonate
gave enantiomerically enriched 2-[(S)-1-cyano-3methyl-butyl]-malonic acid diethyl ester 19. Krapcho
decarboxylation21 of enantiomerically enriched 2-[(S)1-cyano-3-methyl-butyl]-malonic acid diethyl ester 19
gave enantiomerically enriched (S)-ethyl 3-cyano-5methylhexanoate (60% ee) 20 (Scheme VI).
(i)
(S)
(R)
N
O
23
N
O
24
OH
1475
Trade Name
Supplier
% ee
Novozym 435
Lipozyme TL IM
Lipozyme RM- IM
CALB
CALB-lyophilized
Amano AS
Amano AK
Amano PS IM
Amano PS SD
Amano AYS
CLEA
Rhizomucor miehei
Thermomyces langinous
Novozyme A/S
Novozyme A/S
Novozyme A/S
C-LETA
C-LETA
Amano enzyme Japan
Amano enzyme Japan
Amano enzyme Japan
Amano enzyme Japan
Amano enzyme Japan
CLEA Techologies
Sigma
Sigma
99%
@
@
96%
99%
@
@
@
@
@
7%
@
@
1476
160
140
120
100
80
60
40
20
0
0
50
100
150
Time, min
200
(i) 2 % Ethanol
Dry solvent
OH
70 0C
(ii) Acetic acid, RT
(iii) Water, RT
N
26
Yield=95%
N
25
Scheme IX
1477
Route 1
Route 2
Route 3
Route 4
E-Factor
E-Factor (assuming 80% solvent recovery)
Atom economy
Atom efficiency
Reaction Mass efficiency
Carbon efficiency (without considering recycling of undesired isomer)
31.06
9.16
49.93
39.94
22.53
35.33
163.02
29.07
16.23
12.21
3.98
6.31
154.2
55.60
15.09
11.32
2.40
14.37
22.23
4.72
51.70
36.20
29.22
42.37
180
160
140
120
Route 4
Route 1
100
Route 3
80
Route 2
60
40
20
0
E-Factor
E-Factor
(Solvent
Recovery)
Atom
Economy
Atom
Efficiency
Reaction
Mass
Efficiency
Carbon
Efficiency
E - factor =
1478
Carbon efficiency
=
1479
5-Hydroxy-1-[(S)-phenyl-ethyl]-4-iso-butyl-1,5-dihydro-pyrrol-2-one, 3a
1480
1481
1482
1483
1484
1485
1486
A solution of (S)-3-cyano-5-methylhexanoic
acid(20.0 g, 0.13 mol) in methanol:water (50:50) (100
mL) was added to a solution of potassium hydroxide
(7.2 g, 0.13 mol) in water (20 mL) at 25C and was
stirred at RT for 2 h. The mixture was then transferred
into a Parr autoclave reactor and 50% wet palladiumon-carbon (1.0 g) was added carefully. Reactor was
purged with hydrogen gas twice and then 10 atm.
hydrogen pressure was maintained for 24 h. The
reaction mixture was filtered through a Celite pad and
solvent from filtrate was evaporated under reduced
pressure to leave a semi-solid material, which was recrystallized from iso-propyl alcohol:water mixture
(94:06, 25 mL) to obtain (S)-3-(aminomethyl)-5methylhexanoic acid as a white solid (12.0 g, 60%
and 99% ee).
Resolution of (RS)-3-cyano-5-methylhexanoic acid
through diastereomeric salt formation with cinchonidine (1:1 mol ratio) in ethyl acetate
A reactor was charged with cinchonidine (37.9 g,
129 mmol) and ethyl acetate (500 mL) and resulting
reaction mixture was heated to 70C. A solution of
(RS)-3-cyano-5-methylhexanoic acid (20.0 g, 129.0
mmol) in ethyl acetate (200 mL) was added to above
reaction mixture over a period of 15-20 min and
reaction mixture was further stirred for 5 h at reflux
temperature, after which reaction mixture was cooled
to RT and stirred further for 12 h. (S)-3-Cyano-5methylhexanoic acid salt of cinchonidine precipitated
out during this period. The resultant mixture was
filtered to give (S)-3-cyano-5-methylhexanoic acid
salt of cinchonidine as a white solid (28.3 g, 97% ee
for (S)-ethyl-3-cynao-5-methylhexanoate by GC
area%), which was further re-crystalized to obtain (S)3-cyano-5-methylhexanoic acid salt of cinchonidine
(25.3 g, 99% ee for (S)-ethyl-3-cyano-5-methylhexanoate by GC area %). Spectral data is given
below.
IR (neat): 3413, 3071, 2955, 2234, 1639, 1595,
1508, 1394, 1102, 915, 785, 759, 619 cm-1; 1H NMR
(200 MHz, DMSO-d6, Me4Si): 0.89 (d, 3H), 0.91 (d,
3H), 1.30-1.45 (m, 1H), 1.52-1.59 (m, 3H), 1.69-1.82
(m, 4H), 2.38 (bs, 1 H), 2.43-2.55 (dd, 3H), 2.60-2.68
(m, 2H), 2.97-3.07 (m, 2H), 3.25 (s, 1H), 3.49 (s, 1H),
4.93 (d, 1H), 4.99 (d, 1H), 5.64 (d, 1H), 5.78-5.87 (m,
1H), 7.60-7.64 (m, 2H), 7.75 (t, 1H), 8.04 (d, 1H),
8.36 (d, 1H), 8.86 (d, 1H); 13C NMR (DMSO-d6, 50
MHz): 21.6, 22.1, 23.2, 26.2, 26.3, 26.4, 27.6, 38.3,
38.9, 42.3, 55.1, 60.5, 69.4, 115.3, 119.4, 123.0,
124.4, 125.9, 126.9, 129.3, 130.1, 141.6, 148.2, 149.6,
150.5, 172.9; Powder X-ray diffraction pattern PXRD
[2] (Cu K1 = 1.54060 , K2 = 1.54443 , K =
1.39225 ; 40 mA, 45 kV): 5.84, 7.27, 7.69, 10.72,
11.65, 13.79, 14.92, 15.39,15.73, 16.69, 17.31, 17.41,
17.58, 17.99, 19.48, 20.03, 20.71, 21.18, 21.92, 23.18,
24.93, 25.29, 25.95, 26.38, 27.07, 27.91, 28.79, 31.06,
31.65, 35.36, 38.00 and 39.35; DSC Value
(10C/min): Peak = 152.49C, Onset = 149.86C.
Racemization of (R)-ethyl-3-cyano-5-methylhexanoateto (RS)-3-cyano-5-methylhexanoic acid in
dimethyl sulfoxide and 2% ethanol
A reactor equipped with overhead stirring was
charged with (R)-ethyl-3-cyano-5 methylhexanoate
(15.8 g, 0.086 mol), dimethyl sulfoxide (158 mL),
ethanol (4 mL) and sodium ethoxide (7.35 g, 0.10
mol) and the resulting reaction mixture was stirred for
4 h at 75C, after which the reaction mixture was
cooled to RT, neutralized with acetic acid and treated
with water (200 mL) in small portions to maintain the
temperature below 30C. The aqueous phase was
extracted with methyl tert-butyl ether (3 200 mL).
Organic phases were combined and dried over
anhydrous sodium sulfate and solvent was evaporated
under reduced pressure to give (RS)-3-cyano-5methylhexanoic acid as light brown oil (12.5 g, 95%
yield and analyzed by chiral GC by converting to the
corresponding ethyl ester).
IR (neat): 3118, 2961, 2935, 2875, 2642, 2244,
1715, 1470, 1174, 1113 cm-1; 1H NMR (200 MHz,
CDCl3, Me4Si): 0.95 (d, 3H), 0.96 (d, 3H), 1.361.38 (d, 1H), 1.59-1.66 (m, 1H), 1.79-1.85 (m, 1H),
2.59-2.61 (dd, 1H), 2.69-2.75 (dd, 1H), 2.98-3.04 (m,
1H); EI-MS: m/z C8H13NO2: 155.19, [M-H] -: 154.00,
[M+H] +: 156.15.
Racemization
of
(R)-ethyl-3-cyano-5-methylhexanoate to (RS)-3-cyano-5-methylhexanoic acid
in N-methyl pyrrolidone and 2% ethanol
A reactor equipped with overhead stirring was
charged with (R)-ethyl-3-cyano-5 methylhexanoate
(3.0 g), N-methyl pyrrolidone (30 mL), ethanol (0.6
mL) and sodium ethoxide (1.4 g) and the resulting
reaction mixture was stirred for 4 h at 75C, after
1487
1488
References
1 Silverman R B, Andruszkiewicz R, Yuen P, Sobieray D M,
Franklin L C & Schwindt M A, US Patent 5563175,
University Northwestern and Warner Lambert Co, 1966.
2 (a) Bueno L, Chovet M, Diop L, Guglietta A, Little H J,
Rafferty M F, Ren J, Taylozr C P & Watson W P, US Patent
6242488, University of Oklahoma and Warner Lambert Co,
2001; (b) Magnus L & Segal C A, US Patent 6326374,
Warner Lambert Co, 2001; (c) Singh L, US Patent 6001876,
Warner Lambert Co, 1999; (d) Akunne H C, Corbin A E,
Dooley D J, Green A L & Heffner T G, US Patent 6194459,
Warner Lambert Co, 2000; (e) Schrier D, Taylor C P &
Westlund H K N, US Patent 6329429, Warner Lambert Co,
2001; (f) Bueno L, Chovet M, Diop L, Guglietta A, Little H,
Rafferty M F, Ren J, Taylor C P & Watson W P, US Patent
6127418, Warner Lambert Co, 2000; (g) Bueno L, Chovet M,
Diop L, Guglietta A, Little H, Rafferty M F, Ren J, Taylor C
P & Watson W P, US Patent 6426368, Warner Lambert Co,
2001; (h) Magnus L & Segal C A, US Patent 6306910,
Warner Lambert Co, 2001; (i) Pande A C, US Patent
6359005, Warner Lambert Co, 2002.
3 Grote T M, Huckabee B K, Mulhern T, Sobieray D M &
Titus R D, US Patent 5637767, Warner Lambert Co, 1997.
4 Shanghui H, Carlos A M, Junhua T, William E T, Patrick K
& Yves D, US Patent 0283023 (A1), Warner Lambert Co,
2005.
5 Burk M J, Goel O, Hoekstra M S, Mich T F, Thomas,
Mulhern J & Ramsden A, US Patent Appl 0212290 A1,
Warner Lambert Co, 2003.
6 Burns M P, Weaver J K & Wong J W, US Patent Appl
0196905(A1), Warner Lambert Co, 2007.
7 Sammis G M & Jacobsen E N, J Am Chem Soc, 125, 2003,
4442.
8 Kansal V K, Chaurasia B P, Rao V G & Tiwari A P, PCT Int
Appl WO 035890 (A1), Teva Pharmaceutical Industries Ltd,
2007.
9 Kansal V K, Chaurasia B P & Tiwari A P, PCT Int Appl WO
035789 (A1), Teva Pharmaceutical Industries Ltd, 2007.
10 Kansal V K, Chaurasia B P, Tiwari A P & Shelke S H, US
Patent Appl 0306292, Teva Pharmaceutical Industries Ltd,
2008.
11 Blazecka P G, Davidson J G & Zhang J, US Patent 6924377,
Warner Lambert Co, 2005.
12 Silverman R B, Andruszkiewicz R, Yuen P W, Sobieray D
M, Franklin L C & Schwindt M A, US Patent 5563175,
University Northwestern and Warner Lambert Co, 1996.
13 Rasparini M, Tufaro R, Marras G, Giovenzana G & Castaldi
G, PCT Int Appl WO 053446 (A2), Chemo Ibrica S.A, 2009.
14 Anastas P T & Warner J C, in Green Chemistry: Theory and
Practice (Oxford University Press, Oxford), 1998.